A Swiss microbiota biotherapeutics and mucosal vaccines company with two technology platforms: ApyraVax for the generation of innovative mucosal vaccines; ApyraMed with indications in IBD, dysbiosis induced by antibiotic treatments and unhealthy diet, and as enhancer in cancer immunotherapy.

Location
Canton
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2018
  • Number of employees in Switzerland
    1-9
Key business

You may also be interested in